Latest Entitlement Offer News

Page 6 of 111
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
Alara Resources delivered its strongest quarterly copper sales since commercial operations began, while production remained above nameplate capacity at its Oman mine. Yet the company says the parent may need to raise about A$6 million in FY27 to cover a projected cash shortfall.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Range International sharply reduced its quarterly cash outflow while lifting pallet volumes and building a larger rental fleet. But the next phase still depends on a partly subscribed entitlement offer, external funding and several customer opportunities that remain indicative.
Victor Sage
Victor Sage
27 Oct 2026
Prodigy Gold is drilling a deep, untested target at Hyperion while new ore-sorting results strengthen the case for a potential Old Pirate restart. The ASX-listed explorer is also relying on a fully underwritten A$7.92 million entitlement offer after ending the quarter with A$1.95 million in cash and only 1.9 quarters of reported funding.
Maxwell Dee
Maxwell Dee
27 Oct 2026
L1 Global Long Short Fund has completed its entitlement offer, shortfall offers and institutional placement, raising the maximum A$565.4 million available. The capital will be invested under the L1 Global Long Short Strategy, with 321.2 million new shares due to begin trading next week.
Claire Turing
Claire Turing
27 Oct 2026
Altamin has completed the technical work underpinning its Lazio Scoping Study, but pushed the release to the end of Q1 2027 while reporting A$1.56 million in cash and a 1.41-quarter funding estimate. The company has drawn A$1 million from a shareholder-linked facility and is relying on further debt, grant reimbursements, a possible Gorno transaction and potential equity funding to support its plans.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Alara Resources has reported its first full-year profit after its Oman copper operation produced above nameplate capacity, lifting revenue 145% to A$135.3 million. The turnaround is substantial, but negative operating cash flow and a planned A$6 million equity raise keep the balance sheet firmly in focus.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.
Ada Torres
Ada Torres
23 Oct 2026
Whitefield Income more than doubled FY2026 profit to $16 million while raising $187 million and maintaining fully franked monthly dividends. Yet net asset backing per share slipped to $1.23 as investment revaluations weighed on equity.
Claire Turing
Claire Turing
23 Oct 2026
Jatcorp’s revenue rose 23% to $38.9 million in FY2026, but weaker margins, negative operating cash flow and a material going-concern uncertainty leave the nutritional products maker’s recovery unfinished. The company ended the year with $5.6 million in cash after a $4.2 million entitlement offer, while Neurio trademark litigation in China remains unresolved.
Victor Sage
Victor Sage
22 Oct 2026
Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.
Ada Torres
Ada Torres
22 Oct 2026

Browse the archive

Full archive